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The Fragile X Syndrome Protein FMRP Associates
with BC1 RNA and Regulates the Translation
of Specific mRNAs at Synapses
retardation gene (FMR1), which leads to an abnormal
methylation pattern that frequently causes transcrip-
tional silencing of the gene (Verkerk et al., 1991; Oberle`
et al., 1991; Sutcliffe et al., 1992). In addition, rare atypi-
cal cases of Fragile X syndrome have been reported
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binds to 4% of human fetal brain mRNAs, including theErasmus MC
myelin basic protein mRNA (Brown et al., 1998). FurtherDr Molewaterplein
mRNAs that may associate with FMRP and that com-50 Rotterdam
pose a very heterogeneous family have been recentlyThe Netherlands
reported (Sung et al., 2000; Brown et al., 2001). More-
over, specific binding was demonstrated to its own
mRNA in a region that may form a particular structure
called the purine quartet (Ashley et al., 1993; Schaeffer etSummary
al., 2001; Darnell et al., 2001). In mammalian organisms,
there are two FMRP homologs, FXR1P and FXR2PThe Fragile X syndrome, which results from the ab-
(Zhang et al., 1995), which are thought to have distinctsence of functional FMRP protein, is the most common
but overlapping functions. For example, the pattern ofheritable form of mental retardation. Here, we show
expression in brain and testis as well as the subnuclearthat FMRP acts as a translational repressor of specific
distribution mainly overlaps but shows some differencesmRNAs at synapses. Interestingly, FMRP associates
(Tamanini et al., 1997). Several proteins have beennot only with these target mRNAs, but also with the
shown to interact with FMRP. In the cytoplasm, thesedendritic, non-translatable RNA BC1. Blocking of BC1
include FXR1P and FXR2P and the two proteins CYFIP1inhibits the interaction of FMRP with its target mRNAs.
and CYFIP2 (Schenck et al., 2001), while different pro-Furthermore, BC1 binds directly to FMRP and can also
teins interact with FMRP in the nucleus (Bardoni et al.,associate, in the absence of any protein, with the
1999; Ceman et al., 1999, 2000). The presence of anmRNAs regulated by FMRP. This suggests a mecha-
NLS and an NES suggests that FMRP may function asnism where BC1 could determine the specificity of
a shuttle for mRNA export from nucleus to cytoplasm.FMRP function by linking the regulated mRNAs and
Moreover, several lines of evidence suggest that FMRPFMRP. Thus, when FMRP is not present, loss of trans-
could modulate stability and/or translation of its targetlational repression of specific mRNAs at synapses
mRNAs in the cell body and also at the synapses. First,
could result in synaptic dysfunction phenotype of
FMRP was found to associate with ribosomes in the cell
Fragile X patients. body and in dendrites (Eberhart et al., 1996; Khandjian
et al., 1996; Tamanini et al., 1996; Corbin et al., 1997;
Introduction Feng et al., 1997, Weiler et al., 1997; Greenough et al.,
2001). Second, human mRNAs with altered polysomal
FMRP is an RNA binding protein highly expressed in profiles have been identified by probing microarrays us-
the brain. Absence or mutation of FMRP leads to the ing mRNA isolated from polyribosomes of a human frag-
Fragile X syndrome, an X-linked dominant disorder and ile X lymphoblastoid cell line (Brown et al., 2001). Third,
the most frequent cause of inherited mental retardation two different groups have shown that FMRP functions
(1 in 4000 males and 1 in 6000 females). The syndrome is as a nonspecific repressor of translation in vitro (Li et
characterized by mental retardation of variable severity, al., 2001; Laggerbauer et al., 2001) and, more recently,
autistic behavior, macroorchidism in adult males, char- in cotransfection experiments (Mazroui et al., 2002). Fi-
acteristic facial features, and hyperextensible joints (for nally, it has been shown that the Drosophila FMRP regu-
recent reviews see Bardoni and Mandel, 2002; O’Donnell lates futsch, a homolog of the mammalian MAP1B
and Warren, 2002; Oostra, 2002). The syndrome is mRNA, probably at the level of translation (Zhang et al.,
mostly associated with an unstable expansion of a CGG 2001). However, it is not understood how the transla-
repeat located in the 5 UTR of the fragile X mental tional regulation by FMRP works and whether it exhibits
a selectivity for certain mRNAs in vivo.
Here, we show using the FMR1 knockout (KO) mouse*Correspondence: bagni@uniroma2.it
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model that FMRP is a repressor of translation in vivo Quantification demonstrated that some of the den-
dritic messenger RNAs are translated more efficientlyand regulates translation of specific dendritic mRNAs,
including those encoding the cytoskeletal proteins Arc/ in the FMR1 KO mice compared to the wild-type mice
(Figure 1B). In particular, the PMP for Arc increases byArg3.1 and MAP1B, and the kinase -CaMKII. FMRP is
found in a ribonucleoprotein complex that also contains 38% in KO mice while that for -CaMKII and MAP1B
increases by 13% and 17%, respectively. The mRNAsthe small dendritic non-translatable RNA BC1. BC1
binds directly to FMRP and can also associate specifi- of the two FMR1 homologs, FXR1 and FXR2, are also
translated more efficiently in FMR1 KO mice comparedcally with mRNAs regulated by FMRP. These results
strongly suggest that BC1 RNA recruites FMRP to the to the wild-type, presenting a 22% increase in their PMP.
Significantly, this is not a general phenomenon as thetargeted mRNAs, thereby determining the specificity of
FMRP action. distribution of mRNAs encoding GlyR1, GluR1, MAP2,
-Actin, and the non-translatable dendritic BC1 RNA
on the polysome gradient do not change significantlyResults
(Figure 1B). Moreover, Ferritin mRNA, which is involved
in iron metabolism and translationally repressed (PreissFMRP Is a Repressor of Translation
and Hentze, 1999), shows no difference in wild-typeat Synapses
mice compared to FMR1 KO mice.FMRP has recently been shown to be a translational
The data are highly reproducible, and they stronglyrepressor in reticulocyte extracts (Laggerbauer et al.,
indicate that FMRP is a repressor of specific mRNAs in2001; Li et al., 2001). To address the function of FMRP
the brain. Since FMRP is present at synapses (Weilerin the neuronal cell, we analyzed the translational effi-
et al., 1997), we wanted to verify if FMRP is also a transla-ciency of specific neuronal mRNAs of wild-type as well
tional repressor at synapses where protein synthesis isas FMR1 knockout mice (Bakker et al., 1994). We se-
known to occur (for reviews see Martin et al., 2000;lected the mRNAs encoding the following proteins:
Steward and Schuman, 2001; Richter and Lorenz, 2002).MAP1B, the microtubule associated protein 1B, be-
Therefore, we performed polysome/mRNPs analysis ofcause its Drosophila homolog has recently been sug-
extracts from synaptoneurosomes as described abovegested to be translationally regulated by FMRP (Zhang
for the total brain. These preparations are highly en-et al., 2001); MAP2, the microtubule associated protein
riched in synaptic termini and virtually devoid of cell2 (Garner et al., 1988); -CaMKII, the  subunit of Ca2/
body contamination (Bagni et al., 2000).calmodulin-dependent protein kinase II, whose function
We found that the translation of some dendriticallyis associated to synaptic plasticity (Soderling, 2000) and
localized mRNAs is also increased in purified synapto-which is highly expressed at the synapses where its
neurosomes and the increase is, in fact, even higher than inmRNA is translationally regulated (Bagni et al., 2000);
total brain. In particular, the PMPs of Arc and -CaMKIIArc, the activity-regulated cytoskeleton associated pro-
mRNAs increase by 34% and 53%, respectively (Figuretein, also known as Arg3.1 (Lyford et al., 1995; Link et
1B). The MAP1B, -Actin, and Ferritin mRNAs were notal., 1995); the two FMRP homologs, FXR1P and FXR2P;
detectable in the synaptoneurosomes under the sameGlyR1, the  1 subunit of the glycine receptor, and
PCR conditions used to amplify the dendritic mRNAs,GluR1, a subunit of the ionotropic glutamate receptor
while the analysis of GlyR1, GluR1, and MAP2 was notAMPA, because they are thought to play a role in synap-
performed on the synaptoneurosomes because they didtic plasticity (Muller et al., 2002); and, as a control, the
not show any significant difference in total brain extractssmall dendritic RNA BC1 (Tiedge et al., 1991). Since BC1
of wild-type and FMR1 KO mice. In conclusion, several,does not encode a protein, it should not associate with
but not all, mRNAs are translated more efficiently intranslating polyribosomes.
FMR1 KO mice, and this effect is significantly strongerA reliable way to assess mRNA translational efficiency
in isolated synaptoneurosomes as compared to the totalis to analyze its partitioning between actively translating
brain extracts.polysomes and mRNPs that are not translated (Bagni
To determine whether the translational upregulationet al., 2000). To gauge the translational efficiency, the
also leads to higher levels of the proteins in question,percentage of a given mRNA associated with polysomes
we assayed equal amounts of the respective extracts(PMP Percent of Messenger on Polysomes) is quanti-
by quantitative immunoblotting. -Actin was used as afied. Cytoplasmic extracts, prepared from a whole brain
control; as expected, its abundance is not affected inwere fractionated through sucrose gradients (see Exper-
the FMR1 KO (Figure 1C). The level of the other assayedimental Procedures). Ten fractions were collected from
proteins reflects quite well the translational efficiencyeach gradient while recording the absorbance profile
of their mRNAs. Thus, Arc, FXR2P, and MAP1B are more(Figure 1A). Total RNA was extracted from the gradient
abundant in total brain extracts from FMR1 KO versusfractions and then analyzed by quantitative RT-PCR for
wild-type mice, and the effect was much more pronouncedspecific mRNAs. To correct for variations in the effi-
in the synaptoneurosome preparation. For -CaMKII, theciency of the RT-PCR reaction, the same amount of a
increase was observed only in the synaptoneurosomes.synthetic RNA was added to each sample, amplified,
Surprisingly, a significant part of the synaptosomaland used for normalization. Exemplarily, the analysis of
BC1 RNA cosediments with the polysomes of FMR1the -CaMKII mRNA, BC1, and the synthetic control
KO, but not of wild-type mice (Figures 1A and 1B). ThisRNA is shown for the total brain extracts and the synapto-
shows a clear dysregulation of BC1 RNA and demon-neurosomes preparation (see below). In each set of panels,
strates that BC1 RNA has the ability to associate withthe top row shows the distribution of the -CaMKII mRNA,
the middle row BC1, and the bottom the control RNA. large complexes, possibly the translating ribosomes,
FMRP Regulates mRNA Translation at the Synapses
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Figure 1. Polysome/mRNPs Distribution of Dendritic and Cell Body mRNAs
Mouse total brain and synaptoneurosomes extracts were fractionated by sucrose gradient centrifugation. Each gradient was collected in ten
fractions, and an equal amount of synthetic RNA was added to each fraction and then amplified by radioactive RT-PCR. Radioactive signals
in the polysomal and non-polysomal fractions were quantified, corrected versus control RNA, and expressed as PMP (Percentage Messenger
on Polysome). (A) Typical polysomal profile from total brain cytoplasmic extracts and example of RT-PCR reaction performed to detect
-CaMKII mRNA and BC1 RNA association with the polysomal gradient. (B) Polysome/mRNPs analysis in total brain extracts and in synaptoneu-
rosomes. Values shown are the mean  SEM (n  3). (C) Protein level analysis in total brain extracts and synaptoneurosomes. Values shown
are the mean  SEM. The quantitation was repeated three times. *, p  0,05; **, p  0,01; ***, p  0,001 for KO versus W.T. by Student’s t
test in all figures.
but this association is inhibited in wild-type mice by the FMRP sediments on sucrose gradients of brain extracts.
We fractionated cytoplasmic extracts on a continuousFMRP protein.
sucrose gradient, as performed to study mRNA transla-
tion, and analyzed FMRP distribution by Western blotFMRP Associates Mainly
using polyclonal antibodies against the C terminus ofwith Ribonucleoparticles
the human FMRP. This region exhibits no homology toPrevious studies on non-neuronal cell lines have shown
FXR1/2P, and the antibodies do not cross-react withFMRP to be present both in fractions containing the
the FXR proteins (see Experimental Procedures). Inter-polyribosomes and in fractions containing the mono-
estingly, FMRP mainly cosediments with the monomericmeric 80S ribosome (Eberhart et al., 1996; Feng et al.,
80S ribosomes and with mRNPs in the upper fractions1997; Khandjian et al., 1996; Tamanini et al., 1996; Siomi
of the sucrose gradient (Figure 2). A very similar patternet al., 1996; Corbin et al., 1997; Brown et al., 2001; Maz-
of FMRP distribution was detected in a gradient derivedroui et al., 2002). Considering the possibility of a brain-
specific repressor complex, we investigated where from synaptoneurosomes (Figure 2). This distribution is
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munoprecipitate any of the tested RNAs. For these ex-
periments we used stringent salt conditions (250 and
350 mM NaCl). Thus, we conclude that BC1 RNA, Arc
and MAP1B mRNAs specifically associate with FMRP.
A potential BC1 analog in primates is called BC200
RNA (Martignetti and Brosius, 1993; Tiedge et al., 1993).
BC200 RNA, like rodent BC1 RNA, associates with pro-
tein(s) to form an RNP complex (Cheng et al., 1997).
Distribution of the human BC200 reveals a neuron-spe-
cific expression and dendritic localization (Tiedge et al.,
1993), suggesting a role in dendritic RNA transport and/
or translation. This prompted us to investigate whether
BC200 is associated with human FMRP. We specifically
immunoprecipitated the FMRP-RNP particle from hu-
man neuroblastoma, glioma, and lymphoblast cell line
extracts (Figure 3C, left panel), and BC200 was detected
by RT-PCR in extracts from glioma and neuronal cell
lines (Figure 3C, right panel, lanes 4 and 5), but not in
extracts of lymphoblast cell lines (lane 6).
FMRP Binds Directly to BC1Figure 2. Polysome/mRNPs Distribution of FMRP Protein
To assess whether FMRP interacts directly with the BC1Mouse total brain and synaptoneurosomes extracts were fraction-
RNA, we performed electrophoretic mobility shift assaysated by sucrose gradient centrifugation. Each gradient was col-
lected in ten fractions. Absorbance profile of the sucrose gradient (EMSA) using in vitro transcribed, radiolabeled BC1 RNA
from total brain showing the polysomal pattern is reported in the and purified, recombinant FMRP protein or brain ex-
upper part of the figure. An aliquot (same volume) of each fraction tracts (Figure 4). Addition of FMRP protein to the RNA
was analyzed by Western blot using FMRP antibody (rAM1) and, as
leads to formation of an RNP complex that migratescontrol, an antibody for the ribosomal protein S6.
more slowly on the native polyacrylamide gel than the
RNA alone (compare lanes 1 and 2). This complex indeed
contains the FMRP protein since it is shifted by anti-consistent with a role of FMRP as repressor of transla-
FMRP antiserum (lane 3). The binding of FMRP to BC1tion. As control for our experiments, we used the ribo-
RNA is specific and stoichiometric since the complexsomal protein S6 that cosedimented perfectly with the
can be easily competed by a 100-fold excess of unla-polysomes and, as expected, with the 40S ribosomal
beled BC1 RNA, but not by nonspecific competitor tRNAsubunit. This clearly shows that, in brain, FMRP forms
(lanes 6 and 7). It should be noted that recombinantcomplexes different from those previously reported for
FMRP is stable only at 1 M salt concentrations. Sincenon-neuronal cell lines, leading to the initial hypothesis
the protein preparation makes up 75% of the bindingthat in the latter cell lines, the repressor complex is
reactions, the binding occurs at 750 mM salt. This highabsent or less stable.
salt stringency underlines the specificity of the interac-
tion. At the same time, only a small part of the BC1 RNAThe Small Dendritic RNA BC1 Associates
is bound (25%), despite the 2000-fold excess of thewith FMRP
protein. While this may indicate either that the majorityThe finding that BC1 significantly changes its parti-
of the RNA is folded in an unfavorable structure or thattioning on the polysome gradients in the absence of
the high concentration may be too far from physiologicalFMRP prompted us to investigate whether BC1 is asso-
conditions, we believe that the binary complex has aciated with FMRP. For this purpose, we specifically im-
rather high dissociation constant and needs to be stabi-munoprecipitated the FMRP-RNP particle. Antiserum
lized by additional proteins (see Discussion). This notiondirected against the FMRP C terminus, but not preim-
is supported by our finding that BC1 RNA predominantlymune serum, efficiently immunoprecipitates FMRP from
forms a complex in brain extracts that is bigger than themouse brain extracts (Figure 3A). Efficient immunopre-
binary complex (compare lanes 2 and 4). This complexcipitation requires elevated salt concentrations possibly
contains FMRP protein, as judged by its shift upon addi-because the C terminus is masked at physiological salt
tion of anti-FMRP antibodies.concentrations; nevertheless, the antibodies precipitate
a protein complex that also contains FXR1P, a known
FMRP interactor (Figure 3A). To elucidate if the small BC1 Mediates the Interaction between FMRP
and the Regulated mRNAsdendritic RNA BC1 is part of the FMRP complex, total
brain extracts were used to immunoprecipitate FMRP. Since BC1 RNA associates with FMRP, it might well target,
via base-pairing, FMRP to the mRNAs that are to be regu-Analysis of coprecipitating RNA by RT-PCR showed that
FMRP can specifically immunoprecipitate BC1 RNA as lated. To support this hypothesis, we searched for regions
of complementarity between BC1 and the regulatedwell as Arc and MAP1B mRNAs, whereas the -Tubulin
mRNA is not immunoprecipitated (Figure 3B). The bind- mRNAs. We found that nt. 3-21 and nt. 47-70 of BC1 RNA
are predicted to basepair almost perfectly to MAP1Bing specificity was demonstrated by using extracts from
the FMR1 KO mice (lanes 6, 8, 10, 12) as well as from mRNA, while the overlapping region nt. 62-77 is pre-
dicted to basepair with -CaMKII mRNA, and the regionpreimmune serum (data not shown), which did not im-
FMRP Regulates mRNA Translation at the Synapses
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Figure 3. BC1 RNA, Arc, and MAP1B mRNA Are Associated with FMRP Complex
(A) Brain lysates were prepared from wild-type mice and immunoprecipitated in presence of different salt conditions with rAM1 antibody and
probed with 1C3 anti-FMRP. Preimmune serum was used for IP in the upper panel. Similar immunoprecipitates were probed with antibodies
directed against the paralog FXR1P.
(B) Immunoprecipitations were performed from wild-type (lanes 5, 7, 9, 11) and FMR1 KO mice extracts (lanes 6, 8, 10, 12). RNA was extracted,
DNase-treated and RT-PCR was performed using specific oligos for BC1 RNA, Arc, MAP1B, and -Tubulin mRNAs. Shown is the product of
the PCR reactions. Lanes 1, 2, 3, and 4 contain 1/3 of the input (the mRNAs are equally present in the W.T. as well as in the KO extracts).
(C) Immunoprecipitations were performed from human neuroblastoma, glioma, and lymphoblast cell line extracts with rAM1 antibody and
probed with IC3 anti-FMRP (left, upper is preimmune, lanes 1, 2, and 3 contain 1/3 of the input). In a parallel experiment, RNA was extracted,
Dnase treated, and RT-PCR was performed using specific oligos for BC200 RNA. The arrow points to the specific BC200 product while the
asterisk points to a nonspecific product (oligo concatamers). M  100 bp.
between nt. 2-20 of BC1 RNA is predicted to basepair
to Arc mRNA (Figure 5A). Interestingly, the sequence
complementarity is found at the base of the longer stem
loop, according to a stable predicted secondary struc-
ture of BC1 RNA (Rozhdestvensky et al., 2001, Figure 5B).
-Actin mRNA, in contrast, is not regulated by FMRP and
shows no significant complementary to BC1 RNA.
For further support of a direct interaction between
BC1 RNA and the mRNA targets, we designed a 21mer
DNA oligonucleotide that anneals to BC1 RNA in the
region of complementarity to MAP1B mRNA, which has
the longest region of homology among the targeted
mRNAs (the region covering 47-70, oligo BC1-sl-1). Total
brain cytoplasmic extracts were incubated at 37	C with
the BC1 oligo. Then FMRP was precipitated, and the
associated RNAs were analyzed by RT-PCR. Initially,
two concentrations of oligos corresponding to an esti-
mated 150 and 750 molar excess of BC1 were used;
since both gave the same result, we used the lower
concentration in the subsequent experiments.
As shown in Figure 6A, annealing of the specific oligo,
as opposed to a control oligo directed against -Actin
mRNA, reduced coprecipitation of BC1 with FMRP. To
verify whether this reduction was due to either a destruc-
tion of BC1 by an RNaseH activity in the extract or to
an interference of the oligo with FMRP binding to BC1
Figure 4. FMRP Binds Directly to BC1 RNA RNA, we performed the same experiment using a 2O-
methylated RNA oligo (O-Me-BC1 sl-1) that does notEMSA was performed with 32P-labeled BC1 RNA and purified FMRP
or brain extracts. A retarded band is shown (lane 2) due to FMRP induce RNase H degradation of the target mRNA and
interaction with BC1. This band is supershifted after incubation with observed the same reduction in FMRP-BC1 complex
FMRP (rAM1) Ab (lane 3). Three major complexes (black dots) are (Figure 6A). Importantly, no MAP1B mRNA was detected
formed incubating BC1 with brain extracts (lane 4), and two of them
under saturating PCR conditions when the extract wasare destroyed after incubation with rAM1 Ab (lane 5). Competition
treated with the specific BC1 DNA oligo sl-1, whereasexperiments are reported in lanes 6 and 7 with non-labeled BC1
and tRNA, respectively. A reaction with BSA alone is shown in lane 8. treatment with the control oligo caused only a minor
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Figure 5. Homology between BC1 RNA Sequence and the Regulated mRNAs
(A) Mouse BC1 exhibits sequence complementarity to Arc, -CaMKII, and MAP1B mRNAs.
(B) Secondary structure of BC1 RNA has been performed using the program FoldRNA. BC1 sequence is shown in black, while the complementar-
ity of Arc, -CaMKII, and MAP1B mRNAs with BC1 RNA are reported in red, green, and blue, respectively.
(C) Sequence complementarity between human BC200 and the human Arc, -CaMKII, and MAP1B mRNAs.
(D) Secondary structure of BC200 RNA has been performed using the program FoldRNA.
nonspecific reduction of MAP1B mRNA (Figure 6B). it is still not understood how the lack of this protein
causes such a severe clinical phenotype. The morpho-Therefore, we conclude that BC1 is required for the
association of MAP1B mRNA with FMRP. Moreover, the logical anomaly in the brain of both FRAXA patients
and FMR1 knockout mice appears to be limited to theoligo sl-2 directed against the 3 stem loop of BC1 does
not inhibit the FMRP/MAP1B association. These data presence of abnormal dendritic spines, which is reminis-
cent of a delay in maturation (Hinton et al., 1991; Comerydemonstrate the importance of the BC1 region that is
complementary to the target mRNA. et al., 1997). In the FMR1 KO mice, longer and denser
dendritic spines are observed, consistent with the hu-To assay whether BC1 RNA and FMRP-targeted
mRNAs interact in the absence of proteins, an in vitro man phenotype (Nimchinsky et al., 2001). It has been
shown that the level of FMRP increases near synapsesannealing reaction was performed with purified total
brain RNAs and biotinylated BC1 RNA. As shown in in response to neurotransmitter activation (Weiler et al.,
1997), thus FMRP is thought to have an effect on matura-Figure 6C, Arc,-CaMKII, and MAP1B mRNAs coprecip-
itated with biotinylated BC1 RNA. The specificity of this tion and/or function of the synapses (Greenough et al.,
2001). Since both mRNAs and the protein synthesis ma-experiment is shown by the absence of in vitro interac-
tion between BC1 and the neuronal mRNAs like GluR1, chinery are present in dendrites and near postsynaptic
sites (Steward and Schuman, 2001), it is now clear thatGlyR1, and MAP2 (neuronal mRNAs that are not regu-
lated at the translational level by FMRP). This finding local and regulated synthesis of key synaptic proteins
plays an important role in synapsis maturation and neu-strongly suggests a base-pairing interaction between
BC1 and the mRNAs. ronal development.
Interestingly, we show that the mRNAs encoding
FMRP and the two homologs FXR1P and FXR2P areDiscussion
translated at synapses (Figure 1B). The fact that these
proteins are known to interact (Zhang et al., 1995; andFMRP Represses the Translation of Target
Figure 3A) and the fact that all three proteins are synthe-mRNAs at Synapses
sized locally at the synapses suggests that these com-While it is clear that loss of FMRP protein is associated
with the mental retardation of Fragile X (FRAXA) patients, plex(es) can also form in the distal region of the neuron.
FMRP Regulates mRNA Translation at the Synapses
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Figure 7. Model of FMRP Function
The model proposes a direct interaction between BC1 RNA and the
targeted regulated mRNAs. The FMRP RNP is thereby brought into
vicinity of the initiation codon and blocks the translation. Green
rhombi represent Poly(A) binding protein, while the orange and yel-
low figures represent unknown FMRP protein partners.
mRNAs encoding key regulatory proteins, which could
explain how the lack of FMRP could impair the function
of synapses.
BC1 RNA as a Guide to Target FMRP to the mRNAs
that Are Regulated
Several studies have uncovered a variety of mechanisms
through which mammalian gene expression can be reg-
ulated at the level of translation. In many cases, this
happens at the initiation step, where factors can inter-Figure 6. BC1 RNA Interacts with FMRP-Targeted mRNAs
fere, for example, by phosphorylation or proteolyticTotal brain cytoplasmic extracts were incubated in the absence of
oligonucleotides (lanes 1), in the presence of an oligo complemen- cleavage of initiation factors, or by binding to specific
tary to an unrelated RNA (lanes 2), of an oligo complementary to sequence elements in the mRNAs (Preiss and Hentze,
BC1 RNA in the stem loop 1 (lanes 3), or of a modified RNA oligo 1999). Evidence has been reported that FMRP can pre-
O-Me-RNA (lane 4). Then, FMRP was immunoprecipitated and co-
vent the formation of the initiation complexes (Lagger-precipitating BC1 RNA (A) or MAP1B mRNA (B) was amplified by
bauer et al., 2001).RT-PCR. Shown is the product of the PCR reaction fractionated on
Here, we present a model in which BC1 RNA deter-an agarose gel and stained with ethidium bromide. Brain extracts
were also incubated in presence of an oligo complementary to BC1 mines the specificity of FMRP repression (Figure 7). BC1,
RNA in the stem loop 2, FMRP was immunoprecipitated, and co- a non-translatable RNA, is part of an RNP in the brain
precipitating MAP1B mRNA amplified by RT-PCR (Figure 6B, lane (Cheng et al., 1996, 1997). The specific location of BC1
4). M  100 bp. (C) Biotinylated BC1 RNA was incubated with iso-
RNA may indicate a functional role related to transla-lated total RNA from mouse brain and RNAs annealed to BC1 RNA
tional processes in the somatodendritic compartmentswere selected on streptavidin beads. RNA was extracted and RT-
of neurons (Tiedge et al., 1991). Part of BC1 RNA, thePCR was performed using specific oligos for Arc,-CaMKII, MAP1B,
GlyR1, GluR1, and MAP2 mRNAs. Shown is the product of the ID region, is derived from tRNAAla, which has been re-
PCR reactions (lanes 2, 5, 8, 11, 14, 17). Lanes 1, 4, 7, 10, 13, and cruited or adapted into a novel function (Brosius and
16 contain 1/10 of the input. Lanes 3, 6, 9, 12, 15, and 18 show the Gould, 1992). Therefore, it is conceivable that BC1 RNA
same experiment but performed in the absence of BC1 RNA. M 
may interact with ribosomes and may be involved in1 kb plus.
regulating protein synthesis. Moreover, tissue-specific
expression of BC1-like RNA is conserved across mam-
malian species of considerable evolutionary distance,Recent evidence shows that FMRP is a dose-depen-
dent inhibitor of mRNA translation in reticulocyte ex- suggesting that the RNA products have an important
cellular function.tracts and Xenopus oocytes (Laggerbauer et al., 2001;
Li et al., 2001, Schaeffer et al., 2001). In vivo, FMRP could BC1 RNA cofractionated to a significant degree with
the polysome fraction in absence of the FMRP protein.exert a more specific effect. In fact, elegant studies using
Drosophila genetics showed that dFXR, the homolog of This was observed only in the synaptosomal prepara-
tions (Figure 1B), thus linking BC1 RNA to FMRP regula-mammalian FMRP, negatively regulates the expression
of Futsch, a homolog of the mammalian microtubule- tion at synapses. Further analysis demonstrated that
BC1 RNA coprecipitates with the FMRP protein (Figureassociated protein MAP1B (Zhang et al., 2001). Here,
we show that translation of specific mRNAs is up-regu- 3B) and that it can bind directly to FMRP (Figure 4),
establishing a physical link between the two molecules.lated in FMR1 knockout mice. Significantly, the transla-
tional repression by FMRP is much stronger in isolated This association appears to be rather tight, since it was
observed at stringent salt concentrations in immunopre-synaptoneurosomes than in total brain extracts (Figure
1B). Interestingly, the translational repression acts spe- cipitation and band shift experiments. Thus, the interest-
ing model arises in which BC1 RNA binds to FMRP andcifically only on a subset of neuronal mRNAs and affects
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also associates with mRNAs, thus bridging FMRP and the one identified as a possible G quartet. Therefore,
the mRNAs (Figure 7). In this way, BC1 might well be the putative G quartet structures in the target mRNAs
responsible for targeting FMRP to the mRNAs that are could be bound by BC1 RNA.
to be regulated. Since FMRP is thought to inhibit transla- The pathology in the brain of both FRAXA patients
tion at the initiation step, this model predicts that only and FMR1 knockout mice appears to be limited to ab-
a minor fraction of BC1 coassociates with actively normalities in the dendritic spines. Since local protein
translating ribosomes and that this fraction should sig- synthesis is required for synaptic development and
nificantly increase when FMRP and, hence, the block of function, the repressor role of FMRP likely underlies
translation is removed. This is indeed the case. Second, the behavioral and developmental symptoms of FRAXA
the model predicts that BC1 RNA would bind to those patients. The fact that FMRP depletion does not have
mRNAs regulated by FMRP. We found significant a lethal effect suggests that FMRP is a regulator only
stretches of complementarity between BC1 RNA and of a subset of mRNAs whose translation occurs in den-
MAP1B, -CamKII, and Arc mRNAs, and these regions drites. We believe that these data offer new and impor-
are located on the longer stem loop of the BC1 RNA tant insights into the molecular mechanisms of the Frag-
(Figures 5A and 5B). To verify our assumption, we inter- ile X syndrome and translational regulation at synapses.
fered with the putative BC1/mRNA interaction using
RNA oligos and demonstrated that the interaction of Experimental Procedures
FMRP with its target mRNA is lost. Only BC1 stem loop
1 is required for BC1 RNA interaction with the neuronal Antisera
Rabbit polyclonal antiserum rAM1 was raised and affinity purifiedmRNAs analyzed. In this respect, it is interesting to note
against the hexahistidine-tagged C terminus of FMRP. The antibod-that BC1 stem loop 1 has been shown to be required
ies were checked by Western blotting, ELISA, and immunoprecipita-for BC1 localization to dendrites (Muslimov et al., 1997).
tion. Monkey COS-7 cells were transfected with full-length FMR1
Finally, we show that the association between BC1 RNA (ISO7) or the isoform lacking the C terminus (ISO4) and extracts
and FMRP-regulated mRNAs can occur in vitro in ab- analyzed with rAM1 and m1C3 antibodies to validate the C terminus
sence of any protein. The binding is highly specific be- specificity.
cause it occurs in presence of a large population of
mRNAs. Cell Culture
Very recently, it has been shown using the IRES sys- Neuroblastoma (SH-SY5Y), glioma (U373MG) and lymphoblast cell
tem that BC1 RNA can repress translation (Wang et al., lines were grown at a concentration of 105 cells/ml. Lymphoblast
cells were grown in RPMI 1640 supplemented with glutamax and2002). This information supports the role of FMRP-BC1
10% FCS (both GIBCO-Invitrogen) plus antibiotics. Neuroblastomacomplex in the repression of synaptic mRNA translation.
and Glioma cell lines were grown in 50% Dulbecco’s modified Ea-A potential analog of BC1 in primates is called BC200
gle’s medium and 50% F-12HAM.
RNA. Distribution of the human BC200 reveals a neuron
specific expression and dendritic localization, sug-
Protein and RNA Extractiongesting a role in dendritic RNA transport and/or transla-
General procedures for protein and RNA preparation and analysistion. Like BC1 RNA, BC200 RNA can be divided into
followed standard laboratory manuals. Proteins from total brain and
three structural domains: a repetitive element, a central synaptoneurosomes were resuspended in Laemli buffer, boiled,
region, and a unique region. A possible secondary struc- separated by polyacrylamide gel electrophoresis, and transferred to
ture, using computer prediction (Zuker, 1989), revealed Immobilon-P membrane (Millipore), immunostained and visualized
using the SuperSignal Chemioluminescent Substrate (Pierce) or, ifhigh structural homologies to BC1 RNA (Figure 5D) and,
accurate quantitation was required, ECF Western blotting reagentmore interestingly, we could detect a strong comple-
packs (Amersham Pharmacia Biotech). RNAs were prepared frommentarity between BC200 and human Arc, -CaMKII,
total brain, synaptoneurosomes and gradient fractions by Protein-and MAP1B mRNAs. We have shown here that BC200
ase K treatment, phenol/chloroform extraction, and ethanol precipi-
is also able to form a complex with FMRP in neural tation.
tumor cells, so it is highly possible that the two BC RNAs
have the same functional significance.
Polysomes/mRNPs Distribution of mRNAs or ProteinsIn conclusion, we suggest that the specificity of FMRP Animal care was conducted in conformity with the institutional
translational repression is defined through base-pairing guidelines that are in compliance with national (DL N116, GU, suppl
interactions of the associated BC1 RNA. In this model, 40, 18-2-1992) and international laws and policies (European Com-
one of the RNA binding domains of FMRP is most likely munity Council Directive 86/609, OJa L 358, 1, December 12, 1987;
National Institutes of Health Guide for the Care and Use of Labora-responsible for binding to BC1 (Figure 7). Another model
tory Animals, U.S. National Research Council, 1996). Synaptoneuro-has recently been reported in which FMRP binds directly
somes and total brain extract preparation, sucrose gradient sedi-to its target mRNAs. In particular, it has been shown
mentation of polysomes, and analysis of the polysomes/mRNPs
that FMRP binds in vitro to mRNAs that can form G distribution of mRNAs were carried out as described (Bagni et al.,
quartet structures (Darnell et al., 2001; Schaeffer et al., 2000). Total brain or purified synaptosomes were homogenized in
2001). We think that the two binding modes could both lysis buffer (100 mM NaCl, 10 mM MgCl2, 30 mM Tris-HCl [pH 7.5],
occur in the cell, and could possibly be linked to different 1 mM dithiothreitol, 30 U/ml RNasin). After 5 min of incubation on
ice, the lysates were centrifuged for 8 min at 12,000 
 g at 4	C. Thefunctions, e.g., translation and transport of the mRNAs.
supernatants were sedimented in a 5%–70% (w/v) sucrose gradientThis hypothesis is supported by our band shift experi-
by centrifugation for 135 min at 37,000 rpm in a Beckman SW41ments using brain extracts, since several complexes are
rotor. Each gradient was collected in ten fractions. RNA was ex-
formed on the BC1 RNA and only one is clearly shifted tracted from gradient fractions and analyzed by RT-PCR. For protein
by FMRP Ab. We find it interesting that the part of BC1 analysis, the supernatant was sedimented in a 15%–50% (w/v) su-
RNA just before the poly(A) stretch is rather pyrimidine crose gradient by centrifugation for 110 min at 37,000 rpm in a
Beckman SW41 rotor.rich and could thus base-pair with a poly(G) stretch like
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RT-PCR for Polysome/mRNPs Analysis taining 150 mM NaCl. Samples were separated on a non-denaturing
5% polyacrylamide gel. Gel was exposed to a PhosphoImager forRNA samples were extracted DNase treated and reverse transcribed
into cDNA using 100 U of M-MLV RTase (RNaseH, Invitrogen). For quantification.
quantitative RT-PCR analysis, an equal amount (10 pg) of an internal
control RNA was added to each fraction before RNA extraction. Blocking of BC1 RNA by DNA or
This RNA was obtained by in vitro transcription (Ambion, Austin, 2O-Me-oligonucleotide Interference
TX) of the Xenopus ribosomal protein L22 sequence (a.n. X64207) A whole brain was homogenized as described for the immunopre-
and amplified with oligonucleotides annealing to the vector and the cipitation experiments. 1/100 of a brain was incubated in presence
coding region. An aliquot of RT reaction was PCR amplified in a of 300 pmol, estimated to be 150
 excess compared to the endoge-
final volume of 50 l, using 20 pmol of each primer, 100 M of each nous BC1 RNA, or 1500 pmol (750
) of BC1 DNA oligonucleotide
dNTP and 0.5 U of Taq DNA Polymerase (Amersham Pharmacia (BC1 sl-1) or O-Me-RNA oligo (MWG Biotech AG) at 37	C for 20 min.
Biotech). The amount of template and the number of amplification After the incubation, FMRP immunoprecipitation and RT-PCR was
cycles were preliminarily optimized for each PCR reaction, so as to performed as described below.
avoid saturation. For radioactive PCR, dCTP was reduced to 10 M
and 0.2 Ci of -32P-dCTP (Amersham Pharmacia Biotech; 3000 Ci/ RT-PCR for Immunoprecipitated RNAs
mmol) was added. Products were run on a 5% polyacrylamide gel To coimmunoprecipitate RNA, brain lysates were precleared for 1
and quantified by a PhosphoImager. hr with 20 l protein A sepharose (preblocked with 0.1 g/ml each
BSA, yeast tRNA, glycogen) and immunoprecipitated as described
above. DNase I (50 U RNase-free, Amersham Pharmacia Biotech)Mouse Brain Lysate Immunoprecipitation
was added during washes. The immunoprecipitate was treated withWhole brain was washed in cold PBS and homogenized by 10 stroke
50 g proteinase K (Sigma-Aldrich) for 15 min at 37	C. RNA wasdounce homogenization in 2 ml/brain ice cold lysis buffer (10 mM
phenol/chloroform extracted and ethanol precipitated.HEPES [pH7.4]; 200 mM NaCl, 0.5% TritonX-100, 30 mM EDTA) in
First-strand synthesis was achieved using p(dN)6 and 100 U ofpresence of protease inhibitors (Sigma-Aldrich) and 30 U/ml RNasin.
M-MLV RTase (Invitrogen). An aliquot (3 l) was used in a PCRThe following steps were performed according to Brown et al., 2001
reaction with Taq polymerase using gene-specific primers for BC1,with slight modifications. Briefly, nuclei and debris were pelletted
Arc, MAP1B, and -Tubulin.at 8000 rpm in a Eppendorf centrifuge for 10 min at 4	C, the pellet
was washed with 1 ml lysis buffer and pelletted again. Supernatants
FMRP Recombinant Proteinswere pooled, raised to 400 mM NaCl, and clarified at 20,000 rpm in
The DNA plasmid containing the human FMRP C terminus fragmenta Beckman SW41 rotor for 30 min. 300 g of protein extract were
(nt 1545-1899) was a generous gift of Salvatore Adinolfi (MRC, Lon-immunoprecipitated for 1 hr at 4	C with 15 g affinity-purified poly-
don). The construct was expressed in E. coli strain BL21 (DE3).clonal antibodies rAM1 conjugated to 20 l of protein A sepharose
Human FMRP was produced in baculovirus Sf21 cells using a His-(Amersham Pharmacia Biotech). Beads were then washed in lysis
TAT tag in front of the full-length FMRP protein sequence to purifybuffer containing 150, 250, 350, 450, or 550 mM NaCl. The immuno-
the recombinant protein (S.R. and B.O., unpublished data).precipitate was analyzed by 10% SDS-PAGE and Western blotting.
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